Abivax announces full year 2024 financial results

Abivax announces full year 2024 financial results •        cash balance of eur 144.2m as of december 31, 2024; cash runway into q4 2025 full enrollment in phase 3 abtect trial evaluating obefazimod for moderately to severely active ulcerative colitis (“uc”) expected in q2 2025 with top-line results from the 8-week induction trials expected in q3 2025 paris, france – march 24, 2025 – 8:30 am cet – abivax sa (euronext paris: fr0012333284 – abvx / nasdaq: abvx) (“abivax” or the “company”), a clinical-stage biotechnology company focused on developing innovative therapies for chronic inflammatory diseases, announced today its full-year financial results, as of december 31, 2024. the 2024 financial statements, approved by the company's board of directors on march 20, 2025, have been audited by the company's statutory auditors, and the financial reports will be filed with the french and u.s. securities regulatory authorities, respectively, on march 24, 2025.
ABVX Ratings Summary
ABVX Quant Ranking